Vaccines preventing pneumococcal disease protect African children with sickle-cell disease

Apr 28, 2010

A new study released this week in The Lancet Infectious Diseases finds that African children who contract pneumococcus - a bacterial infection that causes pneumonia, meningitis and sepsis - are 36 times as likely to have sickle-cell disease, a blood disorder prevalent in African children that increases the risk for infectious diseases and early death. The study underscores the critical need for use of pneumococcal conjugate vaccines (PCV) among populations predisposed to sickle-cell disease, most notably those in sub-saharan Africa.

"Our findings clearly show that African children with are at increased risk of bacterial illness compared with their peers without sickle-cell disease, with the pneumococcus being of particular concern," said Dr. Keith P. Klugman, contributing author and professor and William H. Foege Chair in Global Health at the Rollins School of Public Health.

Africa is home to the vast majority of the world's sickle-cell disease cases. Sickle-cell disease is inherited by a child from both parents and is caused by abnormal hemoglobin, a that distorts the shape of and delivers less oxygen to tissues. The disease weakens the immune system and puts its victims at risk for serious bacterial infection and childhood death. Data examined from studies in the Democratic Republic of the Congo, Nigeria, Kenya and Senegal - countries with the highest sickle-cell disease burden - clearly demonstrate an increased risk of serious bacterial infection, especially invasive pneumococcal disease, in African children with sickle-cell disease.

"In combination with early diagnosis and treatment of sickle-cell disease, routine, country-wide immunization against pneumococcus is the best strategy to improve quality of life for all African children, particularly those with sickle-cell disease," said Orin Levine, contributing author, executive director of the International Vaccine Access Center (IVAC) at The Johns Hopkins Bloomberg School of Public Health and co-chair of the Pneumococcal Awareness Council of Experts (PACE). "Millions of lives can be saved by improving access to pneumococcal conjugate vaccines."

One-third of all indigenous inhabitants of Sub-Saharan Africa carry the sickle cell gene, and approximately, 230,000 African children are born with sickle-cell disease each year. Because routine access to medical care is out of reach for many children in the region, the average life expectancy for those afflicted with sickle cell disease in Africa is less than 20 years. In many developed countries where comprehensive care including pneumococcal vaccination and aggressive treatment are available, life-expectancy for sickle cell patients is 45-55 years. Since PCV was first introduced in 2000 in the United States, invasive pneumococcal infections in children with sickle-cell disease declined 68 percent in children under 10 and by 90 percent in children under five.

"The one-two punch of sickle-cell disease coupled with pneumococcal disease is devastating in Africa making protecting Africa's children through vaccination an urgent priority," said Ciro A. de Quadros executive vice president of the Sabin Vaccine Institute and co-chair of PACE. "We urge the leaders of African countries to make routine vaccination against pneumococcal disease a priority."

Pneumococcal disease is a that causes life-threatening pneumonia, meningitis and sepsis. Every year, pneumococcal disease takes the lives of nearly 1.6 million people, nearly half of whom are young in the developing world, where vaccines to prevent the disease are not yet in widespread use. The lack of access in these countries has been due primarily to obstacles in awareness, policy guidance and available financing for low-income countries.

Safe and effective vaccines currently exist to prevent pneumococcal deaths. In 2006, the World Health Organization (WHO) recommended that all countries include PCV in their national immunization programs, especially in countries where childhood mortality is high. The WHO recommendation guides country policy-making on the prioritization of measures to address childhood pneumococcal disease.

Explore further: Deadly bacteria released from US high-security lab

More information: To view the full study, please visit www.thelancet.com/journals/lan… ltext#article_upsell

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Global Ebola conference seeks end to W.Africa outbreak

1 hour ago

Leaders of Ebola-hit countries in west Africa will attend an international conference in Brussels Tuesday to mobilise a final push to end the outbreak and ensure the delivery of nearly $5 billion in aid pledges.

High prevalence of HCV in baby boomers presenting to ER

11 hours ago

(HealthDay)—The prevalence of unrecognized chronic hepatitis C virus (HCV) is high among baby boomers presenting to the emergency department, according to a study published online Jan. 28 in Hepatology.

The hidden burden of dengue fever in West Africa

12 hours ago

Misdiagnosis of febrile illnesses as malaria is a continuing problem in Africa. A new study shows that in Ghana, dengue fever is circulating in urban areas and going undiagnosed. The authors of the study hope to use the findings ...

Teenager with stroke symptoms actually had Lyme disease

12 hours ago

A Swiss teenager, recently returned home from a discotheque, came to the emergency department with classic sudden symptoms of stroke, only to be diagnosed with Lyme disease. The highly unusual case presentation was published ...

Understanding lung disease in aboriginal Australians

13 hours ago

A new study has confirmed that Aboriginal Australians have low forced vital capacity—or the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible. The finding may account for ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.